Products
  1. Home
  2. Products
  3. Inhibitors & Activators for IBD Research
Products
Inquiry

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Zotatifin

Cat. No.: IBDI-434241

Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM). Zotatifin induces cell apoptosis.

Size (Solid):

Product Details

Target Eukaryotic Initiation Factor (eIF) | SARS-CoV | Apoptosis
Molecular Weight 487.55
Appearance Solid
Synonyms eFT226
SMILES N#CC1=CC=C([[email protected]@]2(O3)[[email protected]@](C4=C3C=C(OC)N=C4OC)(O)[[email protected]](O)[[email protected]](CN(C)C)[[email protected]]2C5=CC=CC=C5)C=C1
Purity 99.58%

Storage & Handling

Shipping Room temperature in continental US. May vary elsewhere.
Storage Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.
! For research use only, not intended for any clinical use.
Copyright © Ace Therapeutics. All rights reserved.